
TikTok's Hottest Trend: Jaca Jolt from Healthy For Life Foods Sparks a Viral Sensation
Jaca Jolt, sold in a 12-pack of 2 fl oz shots, combines caffeine with essential vitamins B6 and B12 to deliver fast, effective, and long-lasting energy. Its unique formulation is sweetened with Jaca, a 100% pure form of Allulose—a rare sugar with powerful functional benefits. Unlike traditional energy drinks, Jaca Jolt contains no harmful sugar or alternative sweeteners, has zero net carbs, and zero glycemic impact, making it both keto-friendly and diabetic-safe
The star ingredient, Allulose, is GRAS-certified by the FDA (Generally Recognized As Safe) and is associated with a range of health benefits, including support for appetite control and fat burning. With only 5 calories, Jaca Jolt is designed to fit seamlessly into any lifestyle—whether you're at the gym, in meetings, on campus, or managing a full household.
'Jaca Jolt is built for people who live life on the go, and unlike many 2 ounce bottle drinks, is safe for all ages,' said Pete Ferrari, President at Healthy For Life Foods. 'We wanted to create an energy solution that delivers real results—without harmful old school sugar, without excessive amounts of caffeine and other harmful ingredients, without the crash, and without compromise. Seeing our Jaca Jolt go viral on TikTok has been incredibly rewarding. '
The response has been organic and explosive. TikTok videos tagged with #JacaJolt have collectively drawn millions of views. One trending video highlights the caption: 'POV: You're a mom working 12-hour night shifts,' is striking a chord with viewers seeking reliable energy support. Comment sections are filled with praise for its refreshing taste, jitter-free effect, and clean ingredient list. As one user posted, 'Jaca Jolt is a game-changer—no crash, just focus and stamina!'
Whether you're an athlete, a student, a busy parent, or a professional, Jaca Jolt is redefining how we think about energy. It's not just a boost—it's wellness-powered performance.
Jaca Jolt is available now at jacasugar.com. With Healthy For Life Foods leading the charge, this Allulose-powered shot is setting a new standard for energy supplements—and TikTok can't get enough of it.
About Healthy For Life Foods and Jaca Sugar
Healthy For Life Foods is a health and wellbeing company that pioneered the introduction of Allulose—a rare sugar and superfood—to the U.S. market at scale. Through its brand Jaca, HFLF is committed to creating innovative and functional products that support energy, appetite balance, and overall wellness.
Jaca (Healthy For Life Foods)
Media Contact
Company Name: Healthy For Life Foods
Contact Person: Pete Ferrari
Email: Send Email
City: Delray Beach
State: FL
Country: United States
Website: https://jacasugar.com/
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
5 hours ago
- National Post
Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value
Article content SALT LAKE CITY — Echo, the global leader in hydrogen health technology, is responding forcefully to a wave of misinformation being spread by influencers with financial agendas. False claims that the Echo Flask causes heavy metals poisoning or stops working after six months are not only wrong—they're dangerous. Article content 'Hydrogen health is growing fast—and that growth has attracted a swarm of pseudo-scientific influencers using fear, not facts, to push products that pay them more money,' said Josh Carr, CEO of Echo. 'We're done letting those lies go unchallenged.' Article content At the center of the recent smear campaign are false allegations that Echo's hydrogen water bottle stops producing hydrogen after six months and may leach harmful metals. These claims are categorically false, unsupported by any lab data, and contradicted by third-party testing and thousands of happy customers. Article content The Echo Flask is engineered with platinum-coated electrodes, a proprietary proton exchange membrane, and a self-cleaning system—guaranteeing high-concentration hydrogen performance for over 10,000 uses. Echo backs every unit with a 5-year warranty and provides published test results verifying both hydrogen output and water purity. Article content 'These accusations aren't coming from scientists or doctors. They're coming from influencers who make more money when they scare people into buying hydrogen tablets,' Carr said. 'They claim our bottle causes 'heavy metals poisoning,' but produce no lab report, no data—just fear bait.' Article content Echo acknowledges that some low-end hydrogen bottles do degrade quickly—especially those built with cheap electrodes or mass-produced knockoff parts. But the Echo Flask is in a different class: medical-grade materials, clean hydrogen output, and durable construction backed by a decade of engineering. Article content In contrast, hydrogen tablets—often promoted as a better alternative—have major safety, quality, and cost issues. Many contain unregulated magnesium, along with heavy metals like lead, and begin to degrade rapidly the moment you open the package. Article content 'These tablet pushers mislead the public with confusing numbers and manipulated science,' Carr continued. 'They talk about 'high ppm levels' as if that means something useful—but hydrogen dosage is measured in milligrams, not parts per million. A high ppm in a tiny volume can mean a low actual dose. Consumers are literally paying more for less. It's dirty, expensive water with barely any usable hydrogen.' Article content Beyond misleading metrics, tablets are a recurring cost—often over $150/month to match the hydrogen levels the Echo Flask delivers for pennies per day. They're unstable, expensive, and fundamentally misrepresented. Article content 'We've tested these tablets. We've tested our bottles. We publish our data. And we stand behind our technology. That's the difference,' said Carr. 'People deserve truth—not hype.' Article content As the hydrogen wellness category continues to grow, Echo urges consumers to look past influencer theatrics and focus on science, transparency, and value. For third-party test results, hydrogen education, and Echo's full product lineup, visit Article content Article content Article content Article content


CTV News
5 hours ago
- CTV News
UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025
The logo for UnitedHealth Group appears above a trading post on the floor of the New York Stock Exchange, April 17, 2025. (AP Photo/Richard Drew, file) UnitedHealth delivered disappointing second-quarter earnings and went conservative with its 2025 forecast as soaring medical costs continue to swamp insurers. The health care giant said Tuesday expenses that have jumped beyond what it expected when it set coverage prices will continue to pressure its performance. But the company expects a return to earnings growth in 2026. UnitedHealth now expects adjusted earnings of at least $16 per share in 2025 after withdrawing its previous forecast in May. It had started 2025 with expectations of making up to $30 per share. For the full year, analysts forecast earnings of $20.64 per share, according to the data firm FactSet. UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. The Eden Prairie, Minnesota, company also operates a growing Optum business that provides care and technology support. In May, the company withdrew its 2025 forecast due to higher-than-expected medical costs, and CEO Andrew Witty departed the company abruptly. He was replaced by Chairman Stephen Hemsley, who was the UnitedHealth CEO for more than a decade until 2017. That came after the company took the rare step in April of cutting its forecast. That pushed UnitedHealth shares down $130 in its worst single-day performance in over 25 years. Hemsley promised in June that UnitedHealth would establish a 'prudent' 2025 earnings outlook when it detailed second-quarter results. He also said the company had underestimated care activity and cost trends, but improvements were being made. In the second quarter, UnitedHealth reported adjusted earnings of $4.08 per share on $111.6 billion in total revenue. Analysts expected earnings of $4.48 per share on $111.5 billion in revenue, according to FactSet. The company's profit fell 19% to $3.41 billion even as revenue rose 13%. Medical costs, the company's biggest operating expense, jumped 20% to $78.6 billion in the quarter. UnitedHealth is normally the first insurer to report earnings every quarter. But this summer, it followed competitors like Elevance Health Inc. and Centene Corp. that have lowered their annual forecasts and delivered disappointing results. Several insurers say they have been hit by medical costs that are growing faster than expected. Companies have seen a rise in expensive emergency rooms visits and growing prescription drug costs, especially from expensive cancer treatments and gene therapy. They've also seen a rise in behavioral health care, which includes the treatment of mental health conditions and substance use disorders. UnitedHealth shares slid about more than 3% to $272.30 before the opening bell Tuesday. That price topped $630 last November to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. Shares are down 44% so far this year. The Dow Jones Industrial Average, of which UnitedHealth is a member, has climbed 5%. Tom Murphy, The Associated Press


Globe and Mail
5 hours ago
- Globe and Mail
Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL
(LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 study titled 'A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)'. The study aims to evaluate the efficacy and safety of the experimental drug Pirtobrutinib compared to the standard treatment of Bendamustine plus Rituximab in patients who have not received prior treatment for CLL/SLL. The study tests two interventions: Pirtobrutinib, an oral medication, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its potential to offer a more effective and safer treatment option. This interventional study is randomized with a parallel assignment model. Participants are divided equally into two groups, with no masking involved. The primary purpose is treatment, allowing crossover for patients with disease progression. The study began on September 23, 2021, with an active but not recruiting status. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial for tracking the study's development and anticipated results. The outcome of this study could significantly impact Eli Lilly's and Loxo Oncology's stock performance by potentially introducing a new treatment option in the CLL/SLL market. This could influence investor sentiment positively, especially if Pirtobrutinib proves to be a superior treatment. Competitors in the oncology space will be closely monitoring these developments. The study remains active, with further details available on the ClinicalTrials portal.